Kelvin Bao

Clinical Oncologist @ Queen Elizabeth Hospital, Hong Kong |
Interested in breast oncology, cancer survivorship | #travel | #coffee
Tweets are my own.

[Kelvin Bao @khkbao]

A well deserved standing ovation!
Daraxonrasib vs chemo in previously treated advanced pancreatic cancer
mOS 13.2 vs 6.7m in the overall population!

#asco26

[Paolo Tarantino @PTarantinoMD]

Promising results from the TNBC cohort of P-RAD: the addition of preoperative RT + pembro led to significantly increased T-cell infiltration and descriptively higher pCR rate c/w pembro alone. #ASCO26 @TheTBCRC

[Kelvin Bao @khkbao]

#asco26
Fantastic and important insights on the clinical nuances and future development of ADCs by @PTarantinoMD

[Naoto T Ueno, MD, PhD @teamoncology]

SENOMAC study is practice changing, you can omit axillary lymph node dissection for 1-2 macro metastatic disease for T1-3. Are you ready for this practice? #ASCO26

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

Final Analysis at 94 months for KEYNOTE-522 @JavierCortesMD @OncoAlert #ASCO26

[Kelvin Bao @khkbao]

#ASCO26
Thank you @dr_yakupergun for highlighting our work showing the unmet need in the management of ER-low MBC, 1st line CDK4/6i should NOT be considered a default choice for this small but important group.

@jeffreychchan
#bcsm
#ERlow

[Yakup Ergün @dr_yakupergun]

#ASCO26

Does CDK4/6i really work in ER-low disease?

I had also really wanted to study the efficacy of CDK4/6 inhibitors in ER-low tumors, but I could not collect enough data. This study addresses exactly this important question. First of all, congratulations to the investigators.

In ER-low HR+/HER2− MBC, CDK4/6i + ET does not seem to deliver the expected HR+ benefit: PFS was 2.9 months. In ER-high patients, PFS was 23.3 months.

Despite the small sample size and the inherent limitations of a retrospective study, the observed behavior is consistent with what we would expect from ER-low tumors. ER-low disease should not simply be placed into the classic HR+ category with automatic CDK4/6i + ET. This subtype behaves closer to TNBC.

[Kelvin Bao @khkbao]

@dr_yakupergun Thank you very much for highlighting our study, totally agree that the ER-low subgroup deserves more specific management deliberation.

[Paolo Tarantino @PTarantinoMD]

Important to point out that the KATHERINE and DB-05 populations are very different.

- KATHERINE: any residual invasive dz
- DB05: inoperable or node-positive residual dz (very high risk)

In the future, we will have TWO SoC adjuvant treatments for RD, depending on risk

[Paolo Tarantino @PTarantinoMD]

ctDNA analysis of SONIA published on @NatureMedicine. 34% of the patients had high ctDNA before entering the study, and derived a PFS2 benefit from an early (first line) use of CDK4/6-inhibitors. Patients with low ctDNA, instead, derived no benefit. https://t.co/9DMLLo8lOn

[Sara Tolaney @stolaney1]

Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients!

https://t.co/pxI4RxPxXz

[Kelvin Bao @khkbao]

The ADC MASTERCLASS at HKIOF by @PTarantinoMD

#ADC
#HKIOF25

[Kelvin Bao @khkbao]

Fantastic programme and great insights by global experts at the HKIOF2025! So lovely to see @PTarantinoMD in HK, inspirational and beaming with energy as always!

#HKIOF
#InternationalSelfieDay

[Paolo Tarantino @PTarantinoMD]

The curves everybody’s been waiting for.

First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

[Paolo Tarantino @PTarantinoMD]

Sung-Bae Kim presents a phase 3 trial of oral paclitaxel (DHP107) vs IV paclitaxel, mostly conducted in China/Korea. Similar PFS, OS and ORR between the oral and IV formulations. Less neuropathy, but more neutropenia with the oral taxol. We NEED an oral taxane in clinic! #ASCO25

[Paolo Tarantino @PTarantinoMD]

Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment. #ASCO25

[Paolo Tarantino @PTarantinoMD]

Press release: T-DXd + pertuzumab improved PFS vs THP in first-line HER2+ mBC. The T-DXd monotherapy arm remains blinded. The PFS advantage with T-DXd+P is likely to be considerable. Enough to convince breast med oncs to drop the taxane induction strategy? https://t.co/T0gYFdLihm

[Paolo Tarantino @PTarantinoMD]

Otto Metzger (@Otto_DFCI) presents the practice-changing results from the #PATINA phase 3 trial: adding palbociclib to maintenance ET after 1L THP for HR+/HER2+ MBC significantly and meaningfully improved PFS (44 vs 29 months, HR 0.74, p=0.007).

44 months!!!!!!!!!!!!!!!!!!!!!!!!

[Hope Rugo @hoperugo]

#ESMO24 Natalee 4 yr update with increasing benefit in all subgroups c/w carryover effect. 36% <3 yrs; 20% due to AEs. 8.6% gr 3+ LFTs AEs. Nitrosamine issue 2b imminently resolved. Exciting advance for mod/hi risk ES HR+ BC. @OncoAlert

[Paolo Tarantino @PTarantinoMD]

HER2-ultralow officially joins the pie chart of targetable HER2 expressions.

Next step: unlocking the full spectrum with quantitative assays.

#ASCO24 #DB06

[Paolo Tarantino @PTarantinoMD]

Giuseppe Curigliano (@curijoey) presents DB06. Among pts with endocrine-refractory HR+ HER2-low/ultralow MBC, 1L T-DXd significantly & meaningfully improved PFS over chemo (13.2 vs 8.1 mo, HR 0.62, p<0.001). 11% ILD (0.7% G5). New option in the 1L and validation of HER2-ultralow.